<DOC>
	<DOCNO>NCT00071214</DOCNO>
	<brief_summary>Two part study test effectiveness safety StaphVAX vaccine chronic hemodialysis patient infection Staphylococcus aureus .</brief_summary>
	<brief_title>Study Evaluate Effectiveness StaphVAX Adults Hemodialysis</brief_title>
	<detailed_description>Two part clinical trial design evaluate efficacy StaphVAX adult hemodialysis . Part A evaluate prevention bacteremic infection End Stage Renal Disease ( ESRD ) patient interval 3 35 week single dose StaphVAX . Part B study design assess immunogenicity second [ booster ] dose vaccine patient complete Part A , cumulative ( Part A + B ) efficacy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Eligible subject must already receive chronic hemodialysis treatment center participate study . Interested subject discuss enrollment nephrologist . Age 18 year old . Diagnosis chronic endstage renal disease maintenance hemodialysis continuously least eight ( 8 ) week prior enrollment . Hemodialysis access use native vessel fistula synthetic/heterologous graft ( catheter ) . Expectation compliance protocol procedure , visit schedule . Negative serum pregnancy test female childbearing potential ( serum HCG within 7 day prior study drug injection ) . Written informed consent . Known serious S. aureus infection within 3 month study entry . Known recurrent S. aureus infection current graft . Known active viral bacterial infection symptoms/signs consistent infection two week prior injection investigational product . Mild intercurrent viral illness temperature 100.6F less require exclusion , judgement investigator illness interfere evaluation vaccine . Known HIV infection ( test require protocol ) . Known hypersensitivity previous anaphylaxis polysaccharide polysaccharideconjugate vaccine component vaccine . Known suspect abuse drug , prescribe illicit , past year . Current use immunosuppressive immunomodulatory drug ( include systemic glucocorticoid , chlorambucil , cyclophosphamide , azathioprine , methotrexate , cyclosporine , mycophenolate , human immune globulin excess 0.2 g/Kg per month , monoclonal antibody specific human leukocyte subset cytokine , interferon preparation ) , except lowdose physiologic replacement glucocorticoid therapy ( Less equal 10 mg prednisone equivalent per day ) . Known malignancy treatment malignancy within past six month , basal cell squamous cell carcinoma skin . Use investigational drug , product , device within 30 day prior vaccine injection . Presence condition , opinion investigator , place subject undue risk potentially jeopardized quality data generate . Previous administration StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Staphylococcal infection</keyword>
	<keyword>Gram positive bacteria</keyword>
	<keyword>Staphylococcus</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Staphylococcus aureus infection</keyword>
</DOC>